Dmitry Balyasny’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-367,121
| Closed | -$1.47M | – | 1676 |
|
|
2019
Q4 | $1.47M | Sell |
367,121
-748,296
| -67% | -$3.51M | 0.01% | 815 |
|
|
2019
Q3 | $5.47M | Buy |
+1,115,417
| New | +$6.24M | 0.04% | 528 |
|
|
2019
Q2 | – | Sell |
-762,146
| Closed | -$4.43M | – | 1838 |
|
|
2019
Q1 | $4.43M | Buy |
762,146
+216,198
| +40% | +$2.23M | 0.03% | 591 |
|
|
2018
Q4 | $7.35M | Buy |
545,948
+251,504
| +85% | +$4.24M | 0.05% | 422 |
|
|
2018
Q3 | $5.71M | Sell |
294,444
-5,739
| -2% | -$122K | 0.03% | 657 |
|
|
2018
Q2 | $7.67M | Sell |
300,183
-292,636
| -49% | -$6.82M | 0.03% | 560 |
|
|
2018
Q1 | $11.9M | Buy |
+592,819
| New | +$13.8M | 0.05% | 475 |
|
|
2017
Q4 | – | Sell |
-197,171
| Closed | -$4.08M | – | 2457 |
|
|
2017
Q3 | $4.08M | Sell |
197,171
-640,279
| -76% | -$10.8M | 0.02% | 782 |
|
|
2017
Q2 | $12.4M | Sell |
837,450
-1,109,943
| -57% | -$18.5M | 0.05% | 468 |
|
|
2017
Q1 | $31.1M | Buy |
1,947,393
+1,646,178
| +547% | +$23.7M | 0.14% | 180 |
|
|
2016
Q4 | $3.79M | Buy |
+301,215
| New | +$5.61M | 0.02% | 761 |
|
Other funds holding DPLO
Dmitry Balyasny's DPLO Position: Q1 2020 in Review
Dmitry Balyasny sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2020, closing a stake of 367,121 shares — an estimated $1.47M sold.
Dmitry Balyasny first reported a position in DPLO in Q4 2016 and held it in 11 quarters. The position peaked at $31.1M in Q1 2017. 1 fund tracked by Wall St. Rank holds DPLO as of Q1 2020.
- Dmitry Balyasny reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2020 after selling out during the quarter.
- Dmitry Balyasny sold 367,121 DIPLOMAT PHARMACY, INC. shares in Q1 2020, an estimated $1.47M.
- Dmitry Balyasny first reported a position in DIPLOMAT PHARMACY, INC. in Q4 2016 and held it in 11 quarters.
- Dmitry Balyasny's DIPLOMAT PHARMACY, INC. position peaked at $31.1M in Q1 2017.
- 1 fund tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2020.
Based on Balyasny Asset Management's 13F filing for Q1 2020, filed 15 May 2020.